NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

$3.63
+0.04 (+1.11%)
(As of 04/24/2024 ET)
Today's Range
$3.49
$3.70
50-Day Range
$3.25
$4.21
52-Week Range
$1.56
$4.38
Volume
7,722 shs
Average Volume
75,746 shs
Market Capitalization
$190.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.6% Upside
$7.50 Price Target
Short Interest
Healthy
0.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Alimera Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

589th out of 907 stocks

Pharmaceutical Preparations Industry

265th out of 422 stocks

ALIM stock logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

ALIM Stock News Headlines

Alimera Sciences (NASDAQ:ALIM) Upgraded to Buy by StockNews.com
Luckie & Company Acquires Marbury Creative Group
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Luckie & Co. acquires Atlanta marketing agency
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Q4 2023 Alimera Sciences Inc Earnings Call
A Preview Of Alimera Sciences's Earnings
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/25/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALIM
Employees
154
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+106.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-24.83%

Debt

Sales & Book Value

Annual Sales
$80.75 million
Book Value
$0.88 per share

Miscellaneous

Free Float
35,915,000
Market Cap
$190.03 million
Optionable
Optionable
Beta
1.18

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 56)
    CEO & Director
    Comp: $597.87k
  • Mr. David R. Holland (Age 60)
    Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
    Comp: $413.5k
  • Dr. Philip Ashman Ph.D. (Age 59)
    President of International Operations
    Comp: $389.86k
  • Mr. Todd Michael Wood (Age 54)
    President of U.S. Operations
  • Mr. Elliot Maltz CPA (Age 39)
    CFO & Treasurer
  • Mr. Jason Werner
    Chief Operating Officer
  • Christopher S. Visick
    VP, General Counsel & Secretary
  • Dr. David Dyer M.D.
    Chief Retina Specialist

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price target for 2024?

3 analysts have issued 1 year target prices for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 106.6% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2024?

Alimera Sciences' stock was trading at $4.32 at the beginning of 2024. Since then, ALIM shares have decreased by 16.0% and is now trading at $3.63.
View the best growth stocks for 2024 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 108,800 shares, an increase of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is currently 1.3 days.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.02 by $0.09. The biopharmaceutical company had revenue of $26.31 million for the quarter, compared to analysts' expectations of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter in the prior year, the business posted ($0.54) earnings per share.

When did Alimera Sciences' stock split?

Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences issued an update on its FY 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners